Imviva Biotech to Present Clinical Data from Ongoing Phase 1/2 Study of CTA313 at the American Society of Gene & Cell Therapy's Annual Meeting

Imviva Biotech to Present CTA313 Phase 1/2 SLE Data at ASGCT

Imviva Biotech announced it will present clinical data from its ongoing open-label Phase 1/2 study of CTA313, a CD19/BCMA dual-targeted allogeneic CAR-T cell therapy, at the American Society of Gene & Cell Therapy’s Annual Meeting (ASGCT 2026) from May 11-15, 2026. The study evaluates CTA313 in patients with systemic lupus erythematosus (SLE). Results to be presented by Ben Capoccia will demonstrate rapid and profound B-cell depletion, consistent with an immune-reset mechanism, following a single administration of CTA313 in SLE patients. CTA313 is an investigational off-the-shelf therapy designed for B-cell-mediated autoimmune diseases, incorporating proprietary ANSWER™ inhibitory ligands.

• Imviva Biotech is set to present new clinical data on CTA313, its dual-targeted CD19/BCMA allogeneic CAR-T cell therapy, at the ASGCT 2026 Annual Meeting. The presentation will detail findings from an ongoing open-label Phase 1/2 study, specifically focusing on its efficacy in patients with systemic lupus erythematosus (SLE).
• The data to be presented will highlight CTA313's mechanism of action, demonstrating rapid and profound B-cell depletion in SLE patients after a single administration. This immunologic profile is consistent with an immune-reset mechanism, suggesting the potential for durable remission in autoantibody-mediated diseases.
• CTA313 is an innovative off-the-shelf allogeneic CAR-T cell therapy derived from healthy donors, designed for B-cell-mediated autoimmune diseases. It incorporates Imviva's proprietary ANSWER™ inhibitory ligands and genetic edits to enhance resistance to host immune rejection and ensure therapeutic durability.

Addressing Unmet Needs in Systemic Lupus Erythematosus

Current treatment approaches for systemic lupus erythematosus face multiple interconnected challenges that significantly impact patient outcomes. These limitations span from incomplete therapeutic responses and substantial adverse effects to the inherent complexity of the disease itself.

• Incomplete therapeutic efficacy and high failure rates — Only 70-80% of patients with lupus nephritis respond to conventional immunosuppressive therapy, and major clinical trials investigating B-cell-depleting agents rituximab and ocrelizumab failed to meet their primary efficacy endpoints

• Substantial adverse effects from systemic immunosuppression — Traditional therapies including glucocorticoids, cyclophosphamide, mycophenolate mofetil, and azathioprine cause considerable side effects due to their broad systemic activity, with long-term management complicated by the need to minimize immunosuppressive toxicity

• Disease heterogeneity and monitoring challenges — The highly variable clinical presentations of SLE complicate standardized management approaches, while the lack of universally accepted tools for measuring disease activity hampers treatment optimization

• Cardiovascular mortality burden — Cardiovascular disease represents a major cause of death in SLE patients, with many developing subclinical atherosclerosis early in the disease course and facing elevated coronary artery disease risk compared to the general population, driven by lupus-specific factors including chronic inflammation and anticardiolipin antibodies

• Limited pediatric evidence base — Treatment of lupus nephritis in children relies predominantly on adult study data due to insufficient pediatric clinical trial evidence, creating uncertainty in optimal management approaches for younger patients

• Persistent morbidity and mortality from renal involvement — Despite improved overall survival rates, lupus nephritis remains the most important predictor of long-term morbidity and mortality in SLE patients

Promising Phase 1/2 Data for CTA313 in Systemic Lupus Erythematosus

Recent clinical studies have demonstrated promising therapeutic advances for systemic lupus erythematosus across multiple treatment modalities. These trials span from established biologics to novel targeted therapies and innovative cellular approaches, showing encouraging efficacy and generally manageable safety profiles.

Allogeneic CAR-T: Reshaping the Autoimmune Treatment Landscape

The upcoming presentation of CTA313 clinical data marks a pivotal moment for the application of CAR-T technology in autoimmune diseases. Imviva Biotech's dual-targeted CD19/BCMA allogeneic CAR-T therapy for systemic lupus erythematosus (SLE) represents a significant leap from the individualized, costly autologous approaches that have thus far limited the broader adoption of CAR-T outside oncology. The reported rapid and profound B-cell depletion suggests a powerful mechanism for immune reset, offering hope for patients with refractory SLE who currently have limited effective treatment options.

This "off-the-shelf" strategy holds immense promise for overcoming the scalability and commercialization hurdles inherent to autologous therapies. If successful, it could dramatically expand patient access and reduce the logistical complexities of manufacturing. The proprietary ANSWER™ inhibitory ligands are a key component, potentially addressing the critical safety concerns associated with allogeneic cells, such as graft-versus-host reactions and host-mediated rejection.

However, the path forward is not without its considerations. While the potential benefits are substantial, the safety profile of allogeneic CAR-T in an autoimmune setting requires rigorous evaluation. Studies indicate that allogeneic CAR-T is an independent risk factor for infections, including lower respiratory tract infections, which will be a crucial aspect to monitor in this vulnerable patient population. Furthermore, the long-term durability of the immune reset and the potential for sustained immunosuppression or other late-onset adverse events following a single administration will be paramount for establishing the therapy's overall value proposition. The data from ASGCT 2026 will provide critical insights into whether CTA313 can successfully balance potent efficacy with a manageable safety profile, potentially ushering in a new era for autoimmune disease treatment.